Who is sponsoring NCT04410471?

NCT04410471 is sponsored by Magdalena Salcedo.

What drugs are being tested in NCT04410471?

Interventions in NCT04410471: CLIA of IgG and IgM against SARS-Cov-2.

What condition does NCT04410471 study?

NCT04410471 studies Liver Transplant Infection, Covid19, Mortality, Immune Response.

Is NCT04410471 still recruiting?

NCT04410471 is currently status unknown. Last updated 2 June 2020.

Last reviewed 2020-06-02 · How we verify

NCT04410471

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients

Status unknown Last updated 2 June 2020

What this trial tests

trial testing CLIA of IgG and IgM against SARS-Cov-2 in Liver Transplant Infection in 300 participants. Status unknown.

Timeline

29 May 2020

Primary endpoint
29 May 2020

30 June 2021

Quick facts

Lead sponsor	Magdalena Salcedo
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	300
Start date	29 May 2020
Primary completion	29 May 2020
Estimated completion	30 June 2021
Sites	2 locations across Spain

Drugs / interventions tested

CLIA of IgG and IgM against SARS-Cov-2

Conditions studied

Liver Transplant Infection — all drugs for Liver Transplant Infection →
Covid19 — all drugs for Covid19 →
Mortality — all drugs for Mortality →
Immune Response — all drugs for Immune Response →

Sponsor

Magdalena Salcedo

Who can join

Adults 18 to 100, any sex, with Liver Transplant Infection or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective study analyzing the development of humoral immune response against SARS-Cov-2 in patients with previous Covid19: the aim is to compare the incidence, titration and evolution of IgG an IgM in a prospective cohort of liver transplant patients surviving to the first wave of Covid19, in comparison to not inmmunossupressed patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients.
Caballero-Marcos A, Salcedo M, Alonso-Fernández R, Rodríguez-Perálvarez M, et al · · 2021 · cited 34× · PMID 33835707 · DOI 10.1111/ajt.16599
Resilience After COVID-19: A Descriptive, Cross-Sectional Study.
Fernández-Alonso V, Rodríguez-Fernández S, Secadas-Rincón L, Pérez-Gómez M, et al · · 2023 · cited 7× · PMID 36760005 · DOI 10.1177/10547738231154326

Verify or expand the search:

Other recruiting trials for Liver Transplant Infection

Currently open trials in the same condition.

NCT06718517 — Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam- · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04410471 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Magdalena Salcedo
Last refreshed: 2 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04410471.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing